In patients with reduced ADAMTS13 activity and aPL, ADAMTS13 activity should be monitored, and the clinician has to check for thrombocytopenia and hemolytic anemia, the presence of schistozytes, and other clinical and laboratory parameters to discard TMA. Here, ADAMTS13 is linked to Thrombocytopenia.